SOAT1 and COVID-19: Interestingly, one meta-analysis comparing immunomodulatory clinical trials revealed that JAK/STAT inhibitors were highly efficacious at achieving protection from mortality due to COVID-19 along with posing less risk on superimposed infection [173].